Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada. more
Time Frame | ACHV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.55% | 0.31% | -1.26% |
1-Month Return | -23.73% | 0.6% | -4.16% |
3-Month Return | -36.87% | -9.44% | -0.46% |
6-Month Return | -36.36% | -5.15% | 3.58% |
1-Year Return | -25.88% | 0.33% | 22.47% |
3-Year Return | -62.37% | 4.53% | 25.13% |
5-Year Return | -72.55% | 35.98% | 77.7% |
10-Year Return | -99.94% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 254.00K | 255.00K | 250.00K | 236.00K | 228.00K | [{"date":"2019-12-31","value":99.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.04,"profit":true},{"date":"2022-12-31","value":92.55,"profit":true},{"date":"2023-12-31","value":89.41,"profit":true}] |
Gross Profit | (254.00K) | (255.00K) | (250.00K) | (236.00K) | (228.00K) | [{"date":"2019-12-31","value":-25400000,"profit":false},{"date":"2020-12-31","value":-25500000,"profit":false},{"date":"2021-12-31","value":-25000000,"profit":false},{"date":"2022-12-31","value":-23600000,"profit":false},{"date":"2023-12-31","value":-22800000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 16.53M | 14.75M | 33.09M | 40.80M | 27.02M | [{"date":"2019-12-31","value":40.51,"profit":true},{"date":"2020-12-31","value":36.15,"profit":true},{"date":"2021-12-31","value":81.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":66.23,"profit":true}] |
Operating Income | (16.53M) | (14.75M) | (33.09M) | (40.80M) | (27.25M) | [{"date":"2019-12-31","value":-1652800000,"profit":false},{"date":"2020-12-31","value":-1475000000,"profit":false},{"date":"2021-12-31","value":-3309400000,"profit":false},{"date":"2022-12-31","value":-4080000000,"profit":false},{"date":"2023-12-31","value":-2725000000,"profit":false}] |
Total Non-Operating Income/Expense | 303.00K | 89.00K | (41.00K) | (3.14M) | (4.44M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":29.37,"profit":true},{"date":"2021-12-31","value":-13.53,"profit":false},{"date":"2022-12-31","value":-1036.3,"profit":false},{"date":"2023-12-31","value":-1466.34,"profit":false}] |
Pre-Tax Income | (16.39M) | (14.73M) | (33.15M) | (42.35M) | (29.82M) | [{"date":"2019-12-31","value":-1639500000,"profit":false},{"date":"2020-12-31","value":-1473000000,"profit":false},{"date":"2021-12-31","value":-3315200000,"profit":false},{"date":"2022-12-31","value":-4235000000,"profit":false},{"date":"2023-12-31","value":-2981500000,"profit":false}] |
Income Taxes | (254.00K) | (69.00K) | (250.00K) | (475.00K) | - | [{"date":"2019-12-31","value":-25400000,"profit":false},{"date":"2020-12-31","value":-6900000,"profit":false},{"date":"2021-12-31","value":-25000000,"profit":false},{"date":"2022-12-31","value":-47500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (16.14M) | (14.66M) | (32.90M) | (41.88M) | - | [{"date":"2019-12-31","value":-1614100000,"profit":false},{"date":"2020-12-31","value":-1466100000,"profit":false},{"date":"2021-12-31","value":-3290200000,"profit":false},{"date":"2022-12-31","value":-4187500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (16.39M) | (14.73M) | (33.15M) | (42.35M) | (35.57M) | [{"date":"2019-12-31","value":-1639500000,"profit":false},{"date":"2020-12-31","value":-1473000000,"profit":false},{"date":"2021-12-31","value":-3315200000,"profit":false},{"date":"2022-12-31","value":-4235000000,"profit":false},{"date":"2023-12-31","value":-3557100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.14M) | (14.66M) | (32.90M) | (41.88M) | (29.82M) | [{"date":"2019-12-31","value":-1614100000,"profit":false},{"date":"2020-12-31","value":-1466100000,"profit":false},{"date":"2021-12-31","value":-3290200000,"profit":false},{"date":"2022-12-31","value":-4187500000,"profit":false},{"date":"2023-12-31","value":-2981500000,"profit":false}] |
EPS (Diluted) | (42.60) | (6.13) | (4.30) | (4.06) | (1.53) | [{"date":"2019-12-31","value":-4260,"profit":false},{"date":"2020-12-31","value":-613,"profit":false},{"date":"2021-12-31","value":-430,"profit":false},{"date":"2022-12-31","value":-406,"profit":false},{"date":"2023-12-31","value":-153,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACHV | |
---|---|
Cash Ratio | 6.39 |
Current Ratio | 6.78 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACHV | |
---|---|
ROA (LTM) | -54.09% |
ROE (LTM) | -186.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACHV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.35 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.65 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACHV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.64 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Achieve Life Sciences Inc (ACHV) share price today is $3.15
Yes, Indians can buy shares of Achieve Life Sciences Inc (ACHV) on Vested. To buy Achieve Life Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACHV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Achieve Life Sciences Inc (ACHV) via the Vested app. You can start investing in Achieve Life Sciences Inc (ACHV) with a minimum investment of $1.
You can invest in shares of Achieve Life Sciences Inc (ACHV) via Vested in three simple steps:
The 52-week high price of Achieve Life Sciences Inc (ACHV) is $5.59. The 52-week low price of Achieve Life Sciences Inc (ACHV) is $3.12.
The price-to-earnings (P/E) ratio of Achieve Life Sciences Inc (ACHV) is
The price-to-book (P/B) ratio of Achieve Life Sciences Inc (ACHV) is 3.64
The dividend yield of Achieve Life Sciences Inc (ACHV) is 0.00%
The market capitalization of Achieve Life Sciences Inc (ACHV) is $108.33M
The stock symbol (or ticker) of Achieve Life Sciences Inc is ACHV